DelveInsight’s, “Cholangiocarcinoma Pipeline Insight 2023” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Cholangiocarcinoma Pipeline Report

• DelveInsight’s Cholangiocarcinoma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Cholangiocarcinoma treatment.
• The leading companies working in the Cholangiocarcinoma Market include Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
• Promising Cholangiocarcinoma Pipeline Therapies in the various stages of development include Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.
• December 2023: TransThera Sciences (Nanjing) Inc., announced a study of Phase 3 clinical trials for Tinengotinib 8 mg. This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma.
• December 2023: Tyra Biosciences Inc. announced a study of Phase 1 clinical trials for Phase 1 Part A – dose escalation TYRA-200 taken once daily by mouth in 28-day cycles. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
• December 2023: Incyte Corporation announced a study of Phase 3 clinical trials for Pemigatinib, Gemicitabine, and Cisplatin. The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
• December 2023: Servier announced a study of Phase 2 clinical trials for Ivosidenib. This study will enroll participants with nonresectable or metastatic cholangiocarcinoma with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have previously received at least 1, but no more than 2, prior regimens for advanced disease. All participants will receive ivosidenib daily throughout multiple 28 day cycles.

 

Request a sample and discover the recent advances in Cholangiocarcinoma Treatment Drugs @ Cholangiocarcinoma Pipeline Outlook Report

 

In the Cholangiocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Cholangiocarcinoma Overview

Cholangiocarcinoma is an epithelial cell malignancy arising from varying locations within the biliary tree and showing markers of cholangiocyte differentiation. The most contemporary classification based on anatomical location includes intrahepatic, perihilar, and distal cholangiocarcinoma. Many cases of cholangiocarcinoma arise de novo and do not have a specific risk factor, but there are a number of risk factors that have been identified, including primary hepatobiliary disease, genetic disorders, toxic exposures, and infections.

 

Find out more about Cholangiocarcinoma Therapeutics Assessment @ Cholangiocarcinoma Preclinical and Discovery Stage Products

 

Cholangiocarcinoma Emerging Drugs Profile

• Pembrolizumab: Merck Sharp & dohme
• E7090: Eisai
• ABC294640: RedHill Biopharma Limited
• TT-00420: TransThera Science
• KIN-3248: Kinnate Biopharma

 

Cholangiocarcinoma Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the Cholangiocarcinoma therapies. The Cholangiocarcinoma companies which have their Cholangiocarcinoma drug candidates in the most advanced stage, i.e. Phase III include, Merck Sharp & dohme.

 

DelveInsight’s Cholangiocarcinoma pipeline report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

Cholangiocarcinoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging Cholangiocarcinoma Pipeline Therapies @ Cholangiocarcinoma Clinical Trials Assessment

 

Scope of the Cholangiocarcinoma Pipeline Report

• Coverage- Global
• Cholangiocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cholangiocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cholangiocarcinoma Companies- Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
• Cholangiocarcinoma Pipeline Therapies- Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.

 

Dive deep into rich insights for new drugs for Cholangiocarcinoma Treatment, Visit @ Cholangiocarcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Cholangiocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cholangiocarcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pembrolizumab: Merck Sharp & dohme
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. E7090: Eisai
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. KIN-3248: Kinnate Biopharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cholangiocarcinoma Key Companies
21. Cholangiocarcinoma Key Products
22. Cholangiocarcinoma- Unmet Needs
23. Cholangiocarcinoma- Market Drivers and Barriers
24. Cholangiocarcinoma- Future Perspectives and Conclusion
25. Cholangiocarcinoma Analyst Views
26. Cholangiocarcinoma Key Companies
27. Appendix

 

For further information on the Cholangiocarcinoma Pipeline therapeutics, reach out to Cholangiocarcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market